Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
We report a young male patient who developed plasma cell myeloma/plasmacytoma 11 years after having received an allogeneic hematopoietic cell transplantation for AML. The patient received a second transplantation from the same donor without immunosuppression and developed graft-versus-host disease (GVHD). Our observation has two aspects that warrant attention: first, insufficiency of long-term tolerance to prevent GVHD in the absence of immunosuppression and second, a stromal or genetic susceptibility to develop hematologic malignancies despite of a complete donor-type chimerism.
Stem Cell Transplantation Unit, Hematology Department, Ankara University Medical School, Dikimevi, 06590 Ankara, Turkey.
Sule Mine
SM
Bakanay
Esin
E
Serbest
Klara
K
Dalva
Isinsu
I
Kuzu
Meral
M
Beksac